Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Genprex Inc (GNPX)

Genprex Inc (GNPX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 244,082
  • Shares Outstanding, K 43,277
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,650 K
  • 60-Month Beta -0.55
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.73
Trade GNPX with:

Options Overview

Details
  • Implied Volatility 139.52%
  • Historical Volatility 130.74%
  • IV Percentile 72%
  • IV Rank 10.03%
  • IV High 930.67% on 03/16/20
  • IV Low 107.88% on 03/01/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 12
  • Volume Avg (30-Day) 1,291
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 5,042
  • Open Int (30-Day) 21,072

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.14
  • Growth Rate Est. (year over year) +713,671.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.01 +14.90%
on 02/26/21
7.72 -25.44%
on 02/08/21
+0.13 (+2.25%)
since 02/03/21
3-Month
3.18 +80.73%
on 12/09/20
7.72 -25.44%
on 02/08/21
+2.40 (+71.58%)
since 12/03/20
52-Week
1.49 +286.34%
on 03/16/20
7.72 -25.44%
on 02/08/21
+1.33 (+29.94%)
since 03/03/20

Most Recent Stories

More News
Genprex to Participate in Upcoming March Investor Conferences

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that it will...

GNPX : 5.42 (-3.90%)
Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced it has entered...

GNPX : 5.42 (-3.90%)
Genprex Announces Formation of Clinical Advisory Board

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the...

GNPX : 5.42 (-3.90%)
Small and Microcap Company Investor Presentations Now Available for On-Demand Viewing

, /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the Small and Microcap Showcase are now available for...

BIGG.CN : 1.450 (+11.54%)
NTAR.CN : 5.200 (-1.89%)
MIRI.LN : 51.000 (-3.77%)
BBKCF : 1.1500 (+10.96%)
EXPFF : 0.3251 (-2.34%)
MMDDF : 0.6970 (+2.50%)
NEXCF : 4.1800 (+0.48%)
ALVOF : 0.6925 (+10.57%)
ETIHY : 4.2900 (+10.00%)
LLEIF : 7.9300 (unch)
GNPX : 5.42 (-3.90%)
BSGM : 4.51 (-1.31%)
VNRX : 3.94 (-2.23%)
CTXR : 1.94 (-3.96%)
VERB : 2.03 (-2.40%)
LGIQ : 6.9400 (-3.34%)
CETY : 0.0873 (+2.71%)
SLBG : 3.3100 (-1.78%)
SKYE : 0.0955 (+6.11%)
Genprex Recognizes World Cancer Day

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announces today that...

GNPX : 5.42 (-3.90%)
Genprex Issues Shareholder Letter and Provides Corporate Update

--Company looks toward launching key clinical trials in lung cancer in 2021

GNPX : 5.42 (-3.90%)
Live Investor Conference & Webinar: Small and Microcap Company Showcase on February 4th

, /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Small and Microcap Showcase.  Individual investors, institutional...

VNRX : 3.94 (-2.23%)
BIGG.CN : 1.450 (+11.54%)
MIRI.LN : 51.000 (-3.77%)
BSGM : 4.51 (-1.31%)
GNPX : 5.42 (-3.90%)
VERB : 2.03 (-2.40%)
CTXR : 1.94 (-3.96%)
EMBI : 0.0900 (+1.69%)
SKYE : 0.0955 (+6.11%)
BBKCF : 1.1500 (+10.96%)
CETY : 0.0873 (+2.71%)
EXPFF : 0.3251 (-2.34%)
MMDDF : 0.6970 (+2.50%)
SLBG : 3.3100 (-1.78%)
ALVOF : 0.6925 (+10.57%)
ETIHY : 4.2900 (+10.00%)
LGIQ : 6.9400 (-3.34%)
LLEIF : 7.9300 (unch)
Genprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that...

GNPX : 5.42 (-3.90%)
Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that...

GNPX : 5.42 (-3.90%)
Genprex to Present at NobleCon17 on January 19

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that...

GNPX : 5.42 (-3.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Genprex Inc. operates as a biotechnology company. It discovers and develops immunogene therapies for cancer treatment as well as clinical research, gene therapies, consulting and other related medical services. The company's initial product candidate is Oncoprex(TM) immunogene therapy which treats non-small...

See More

Key Turning Points

3rd Resistance Point 6.19
2nd Resistance Point 5.97
1st Resistance Point 5.80
Last Price 5.42
1st Support Level 5.41
2nd Support Level 5.19
3rd Support Level 5.02

See More

52-Week High 7.72
Last Price 5.42
Fibonacci 61.8% 5.34
Fibonacci 50% 4.61
Fibonacci 38.2% 3.87
52-Week Low 1.49

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar